Prenatal Screening Test Comprehensive NIPT (VERAgene) -Non-invasive Prenatal Screening for Your Baby’s Health

Regular price £479.99 ~~£523.99~~
Order within

To receive your order

Non-invasive Prenatal Screening for Your Baby’s Health

There is no age limit. VERAgene can be used by pregnant women of any age since it tests for a wide range of genetic disorders with no age-related risk.

WHAT IS VERAgene?

VERAgene is the first non-invasive prenatal diagnostic that can screen for aneuploidies, microdeletions, and single gene illnesses all at the same time. VERAgene screens for illnesses that are frequently severe and have a considerable influence on quality of life. Congenital malformations, developmental delays, hearing loss, blindness, metabolic issues, and other symptoms are common with these hereditary illnesses.

WHAT ARE GENETIC CONDITIONS?

Unwanted alterations in the DNA that occur during conception create genetic disorders. The test detects three types of genetic conditions:

Aneuploidies are genetic conditions that occur when a chromosome has an extra copy (trisomy) or is missing a copy (monosomy).
Microdeletions are genetic conditions caused by a small deletion in a specific region of a chromosome.
Single-gene diseases are genetic conditions caused by mutations in a gene.

WHY SHOULD A PREGNANT WOMAN DO THE VERAgene TEST?

Unlike aneuploidies, microdeletions and single gene illnesses are not connected with maternal age, and the majority of them lack chemical or ultrasound indicators that can aid in early diagnosis. Based on high and moderate-risk pregnancies, the cumulative risk for the foetus being impacted by one of the genetic diseases tested by VERAgene is around 1 in 50. VERAgene can properly test for these disorders, allowing parents to make educated decisions regarding potential therapies and clinical care.

HOW DOES VERAgene WORK?

WHAT CONDITIONS CAN BE DETECTED BY VERAgene ?

VERAgene can detect trisomies of chromosomes 21, 18, 13, aneuploidies of X and Y chromosomes, DiGeorge syndrome, 1p36 deletion syndrome, Smith-Magenis syndrome and Wolf-Hirschhorn syndrome. VERAgene targets 2000 mutations to screen for 100 monogenic diseases. By combining the detection of aneuploidies and microdeletions with the screening of monogenic diseases.